Alpha inflation [Design Issues]

posted by d_labes  – Berlin, Germany, 2016-05-03 18:06 (3204 d 02:28 ago) – Posting: # 16273
Views: 7,987

Dear Ohlbe,

❝ Any idea about alpha inflation control with such a design ?


If the evaluation follows the same line as the EMA recommends for 3- or 4-period studies, namely forget all the data not involved in the respective comparison, the same alpha inflation as for a usual partial replicate design is expected.

See
Munoz et al.
"Consumer’s risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs"
Stat Med. 2016 May 30;35(12):1933-43.
doi: 10.1002/sim.6834. Epub 2015 Dec 28.

The method to control the TIE is coming soon ... :cool:
Meanwhile see this thread and links therein.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,662 registered users;
243 visitors (0 registered, 243 guests [including 12 identified bots]).
Forum time: 19:34 CET (Europe/Vienna)

There are sadistic scientists who hurry to hunt down errors
instead of establishing the truth.    Marie Curie

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5